Video resource

Video series: Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple Myeloma

View our national broadcast, led by Dr. Brooke Peters, PharmD, BCOP, and the Clinical Pharmacy Services Manager of Pharmacy Operations at the American Oncology Network, as she shares insights on key considerations for operationalizing bispecific therapies in patients with relapsed or refractory multiple myeloma.

In these videos, Dr. Peters explores three states of readiness that can support successful operations:

Facility readiness

Offers helpful information regarding:

• The importance of an operational champion, along with their potential roles and responsibilities
• REMS processes and requirements for healthcare facilities
• The importance of establishing a standard operating procedure (SOP) and treatment protocols for bispecific therapies, including education and training plans, transition of care coordination, roles and responsibilities, and adverse reaction (AR) management
• Key financial questions to consider when onboarding bispecific therapies, including coverage, coding, and cost

Watch This Segment

Healthcare provider and care team readiness

Discusses details such as:

• Staff education and potential areas of bispecific education
• Navigating the multi-phase treatment journey, including site of care and care coordination
• Care coordination when transitioning care, including site preparedness, process alignment, care center responsibilities, and approaches for information transfer
• Unique dosing considerations for RRMM bispecific therapies, including scheduling, site of administration, pre-medication, and preparation and administration
• Select adverse reaction screening, monitoring, and management, including considerations for CRS, ICANS, and infections

Watch This Segment

Patient and care partner readiness

Reviews important considerations that include:

• Logistical preparedness, such as travel, transportation, and access and affordability
• Care partner support, including the essential role they play in helping to monitor a patient on bispecific therapy
• Educating patients and care partners on treatment expectations

Watch This Segment

Informational publication

Article outlining recommendations from a panel of academic and community practice pharmacists with experience using bispecific antibodies in clinical trials and standard of care

Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination